文献速递免疫规划传染病防控与疫情报告

威尔士大规模队列14年随访:麻疹与腮腺炎疫苗效果估计

Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK.
PubMed 文献 · Int J Epidemiol · 2026-01-01

该研究基于威尔士822 116名1-30岁人群的回顾性队列,随访2007至2020年,评估含麻疹和腮腺炎成分疫苗的长期效果。结果显示,两剂疫苗对实验室确诊麻疹的保护在15年后仍高达99.7%,而对腮腺炎的保护随时间下降,第二剂后5年内为93.6%,≥15年后降至49.9%,第三剂可暂时提升保护至87.6%。

要点

  • 两剂麻疹疫苗15年后调整VE仍达99.7%(95%CI 99.2-99.9)。
  • 腮腺炎疫苗第二剂后5年内aVE为93.6%,≥15年降至49.9%。
  • 第三剂腮腺炎疫苗可暂时将aVE提升至87.6%(95%CI 71.7-94.6)。

核心结论

  • 麻疹疫苗高且持久的保护支持消除目标仍可实现。
  • 腮腺炎疫苗保护随时间衰减,第三剂在暴发场景中可考虑使用。

研究设计与样本

  • 通过数据链接获取疫苗接种状态、实验室确诊和通知数据,采用扩展Cox回归计算风险比。

主要发现

  • 两剂疫苗后15年,对实验室确诊麻疹的调整VE为99.7%(95%CI 99.2-99.9)。
  • 对实验室确诊腮腺炎的调整VE在第二剂后5年内为93.6%(95%CI 90.2-95.8),≥15年后为49.9%(95%CI 34.4-61.8)。
  • 第三剂腮腺炎疫苗的调整VE为87.6%(95%CI 71.7-94.6)。
  • 基于临床疑似病例计算的腮腺炎aVE较低。
  • 两种感染的并发症VE均较高。

临床怎么用

  • 维持两剂麻疹疫苗高接种率以巩固消除状态。
  • 腮腺炎暴发时评估第三剂疫苗的临时保护作用。
  • 利用数据链接持续监测疫苗效果变化。

局限性

  • 研究为回顾性设计,可能存在未测量混杂。
  • 结果基于威尔士特定人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uptake of the measles-mumps-rubella vaccine in Wales is high. However, sporadic measles cases still occur and there are large mumps outbreaks every few years. In this study, the long-term vaccine effectiveness (VE) of vaccines containing measles and mumps is assessed. METHODS: A retrospective cohort of 822 116 individuals aged 1-30 years were followed up between 1 January 2007 and 31 December 2020. Welsh Demographic Service data were linked to vaccination status from the national vaccination register and primary care records. Outcomes were identified by linking to laboratory confirmations (measles and mumps) and notifications (mumps) data. Complications were sourced from hospital admissions and primary care data. Extended Cox regression was used to calculate hazard ratios. RESULTS: The adjusted VE (aVE) against confirmed measles after two doses remained high after 15 years 99.7% [95% confidence interval (CI) 99.2-99.9]. The aVE for confirmed mumps was lower, with decline over time: 93.6% (95% CI 90.2-95.8) in the first 5 years after vaccination with dose two and 49.9% (95% CI 34.4-61.8) after ≥15 years. A third dose of mumps vaccine temporarily increases protection (87.6%, 95% CI 71.7-94.6). The aVE estimates for mumps were lower when based on clinical suspicion. The VE was high against complications for both infections. CONCLUSION: The high, sustained VE for measles strengthens evidence that elimination remains possible and the high VE against mumps complications is encouraging. Evidence for the waning of mumps immunity may be important when deciding to implement a third dose in outbreak settings. With the increased use of data linkage, studies should be conducted to corroborate these findings.

来源:Int J Epidemiol,查看原文。版权归原作者所有。

引用

  1. Perry M, Gravenor MB, Cottrell S, et al. Estimates of vaccine effectiveness against measles and mumps: 14 years follow-up of a large cohort in Wales, UK. Int J Epidemiol. 2026. PMID: 42250256. doi:10.1093/ije/dyag083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。